NEW ORLEANS — In this video perspective, Nikhil C. Munshi, MD, discusses presentations from the ASH Annual Meeting and Exposition that focus on advances in bispecific antibody treatments for patients with multiple myeloma.
New data on teclistamab, elranatamab, alnuctamab and two studies that looked at combinations of bispecific therapies are highlighted.
“Bispecifics are here to stay,” Munshi, a professor of medicine at Harvard Medical School, said.
“They are becoming an important part of our treatment, currently as a fifth line and beyond, but very strong. In combination we will be
